BFF BK SPA by BFF BK SPA Azioni (OTC: BFFBF)

Ultime notizie per BFF BK SPA by BFF BK SPA (OTC:BFFBF) Azioni

BFF BK SPA by BFF BK SPA

Barclays analyst Jason Goldberg maintains Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Overweight and lowers the price target from $760 to $720.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Goldman Sachs Group, Lowers Price Target to $720

Stephens &amp; Co. analyst Mike Scialla maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and lowers the price target from $59 to $57.

Stephens & Co. Maintains Overweight on EQT, Lowers Price Target to $57

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">47.221</td>
<td align="right">0.071</td>
<td align="right">0.15</td>
<td>278.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">200.270</td>
<td align="right">0.110</td>
<td align="right">0.05</td>
<td>67.9K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">81.0500</td>
<td align="right">-0.420</td>
<td align="right">-0.52</td>
<td>4.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">78.8700</td>
<td align="right">-0.300</td>
<td align="right">-0.38</td>
<td>46.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">126.5200</td>
<td align="right">-0.460</td>
<td align="right">-0.37</td>
<td>3.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">138.2200</td>
<td align="right">-0.320</td>
<td align="right">-0.24</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">77.5506</td>
<td align="right">-0.139</td>
<td align="right">-0.18</td>
<td>3.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.5900</td>
<td align="right">-0.130</td>
<td align="right">-0.16</td>
<td>3.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">190.0500</td>
<td align="right">-0.220</td>
<td align="right">-0.12</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">91.8700</td>
<td align="right">-0.010</td>
<td align="right">-0.02</td>
<td>2.2K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 15, 2025

Barclays analyst Dan Levy maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Equal-Weight and lowers the price target from $47 to $37.

Barclays Maintains Equal-Weight on Magna International, Lowers Price Target to $37

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.60</a>.
The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year over year and beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44806571/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">of $21.58 billion</a>.
Operational growth was 4.2%, and adjusted operational growth was 3.3%. Innovative Medicine sales increased 2.3% or 4.2 operationally to $13.90 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44737545/johnson-johnson-protagonist-partnered-investigational-psoriasis-oral-pill-shows-75-of-adolescents-achieved-completely-clear-skin" rel="noreferrer noopener">Johnson &amp; Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study</a>
Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, Spravato (esketamine) Neuroscience, and Xarelto in cardiovascular. Growth was partially offset by an approximate (810) basis points impact from Stelara <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44808099/johnson-johnson-reports-q1-2025-results" rel="noreferrer noopener">(ustekinumab) in immunology</a>.
Cancer sales increased to $5.68 billion, up 17.9% (+20.4 operational).
Immunology sales fell to $3.71 billion, down 12.7% (down 10.9% operational).
Stelara sales&nbsp;<a target="_blank" href="https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/1Q25-Earnings-Press-Release-Final-Draft-4-14-with-Attachments.pdf" rel="noreferrer noopener">fell</a> 33.7% to $1.63 billion. Darzalex sales rose 20.3% to $3.24 billion. The company&#8217;s cancer cell therapy, Carvykti, generated sales of $369 million.
MedTech sales increased 2.5% to 8.02 billion, driven primarily by Abiomed in cardiovascular and wound closure products in general surgery. Growth was partially offset by Spine, Sports &amp; Other in Orthopaedics.
Dividend: Johnson &amp; Johnson also announced an increase in its quarterly dividend from $1.24 to $1.30 per share. The 4.8% increased dividend is payable on June 10, with a record date of May 27.
Guidance:&nbsp;Johnson &amp; Johnson expects 2025 sales of $91 billion-$91.8 billion versus <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">prior guidance of $90.9 billion–$91.7 billion</a> and consensus of $90.62 billion
The Medtech giant expects 2025 adjusted operational EPS of $10.50-$10.70, compared to prior guidance of $10.75–$10.95. It maintained the adjusted EPS outlook of $10.50-$10.70 versus the consensus of $10.50.
Adjusted operational EPS excluded the impact of translational currency, which means JNJ anticipates a hit to the bottomline from the impact currency.
The company anticipates second-half operational <a href="https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/Final-JNJ-Earnings-Presentation-Q1-2025-Webcast.pdf" target="_blank" rel="noreferrer noopener">sales</a> growth higher than the first half of 2025. 
Johnson &amp; Johnson said the increase in full-year 2025 operational sales&nbsp;guidance reflects the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition.
Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, the company maintains a full-year 2025 adjusted reported EPS&nbsp;outlook of 6.2% growth at the mid-point.
In March, Johnson &amp; Johnson&nbsp;announced its plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.
Price Action: JNJ stock is down 0.88% at $153.01&nbsp;during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44801588/bofa-sees-mostly-inline-q1-for-industrials-highlights-3m-jci-ge-vernova-as-top-picks" target="_blank" rel="noreferrer noopener">BofA Sees Mostly Inline Q1 For Industrials, Highlights 3M, JCI, GE Vernova As Top Picks</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Dividends

Health Care

General

Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit

TORO

Toro Q4 EPS $(0.01) Down From $0.18 YoY; Total Vessel Revenue $5.228M Down From $7.297M YoY

Stephens &amp; Co. analyst Mike Scialla maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Overweight and lowers the price target from $90 to $86.

MTDR

Stephens & Co. Maintains Overweight on Matador Resources, Lowers Price Target to $86

Barclays analyst Dan Levy maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Equal-Weight and lowers the price target from $115 to $85.

Barclays Maintains Equal-Weight on Lear, Lowers Price Target to $85

Non-opioid, multi-mechanism profile positions Mazindol as a differentiated&nbsp;asset in addiction therapeutics
Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy
ZURICH, April 15, 2025 /PRNewswire/ -- <a href="http://www.nlspharma.com/">NLS Pharmaceutics Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSPW#NASDAQ">NLSPW</a>) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced conditioned place preference (CPP) in mice. The study, conducted by Key-Obs SAS, a leading preclinical CRO, provides evidence that Mazindol may offer a novel, non-opioid approach for the treatment of fentanyl use disorder — a condition contributing to over 75% of opioid-related overdose deaths in the United States.
As the United States continues to battle the devastating effects of the fentanyl epidemic — now the leading cause of death for Americans aged 18–45 — the urgency for effective, non-opioid treatment options has never been greater. Addressing the crisis has become a renewed national priority, underscored by continued federal initiatives to combat the opioid epidemic and renewed efforts to thwart the flow of illegal opioids into the country. The U.S. opioid and broader substance use disorder treatment market, valued at over $35 billion in 2021, is projected to exceed $60 billion by 2029, driven by the immediate demand for safer, more effective alternatives to traditional opioid-based therapies.
 &nbsp;

NLSP

NLS PHARMACEUTICS LTD WT PUR COM SER A EXP

NLSPW

NLS Pharmaceutics Says Results From Study KO-943 Provides Evidence That Mazindol May Offer Non-Opioid Approach For Treatment Of Fentanyl Use Disorder

Mizuho analyst Siti Panigrahi maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Neutral and lowers the price target from $11 to $9.

Mizuho Maintains Neutral on ZoomInfo Technologies, Lowers Price Target to $9

Disguise, Inc., a prominent global leader in the costume industry, and a subsidiary of global toy and consumer products leader JAKKS Pacific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>), is proud to announce a multi-year licensing agreement with SEGA of America, Inc. granting Disguise the sole rights to create Sonic the Hedgehog costumes for distribution across North America, Europe, the Middle East, Africa (EMEA), and Latin America (LATAM), this commences, Disguise's entitlement as the sole costume manufacturer developing products based on the Sonic the Hedgehog core IP.
Disguise has already developed full costume lines for major Sonic the Hedgehog properties, including Sonic Prime, Sonic the Hedgehog 2, and the highly anticipated Sonic the Hedgehog 3. These collections have been met with enthusiastic fan response, cementing Disguise's reputation as the go-to brand for Sonic-themed costumes. With this new agreement, Disguise will continue to expand its Sonic offerings, ensuring fans can continue to bring their favorite blue blur to life through costumes.

JAKK

JAKKS Pacific's Disguise Secures New Rights To The Core IP For Sonic The Hedgehog In Multi-Year Deal With SEGA Of America

Bank Of America Says Total Consumer Loan Decrease Reflected A Concentrated Effort On Us To Focus On Relationship Loans Rather Than Loans As A Product

Mizuho analyst Siti Panigrahi maintains Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Outperform and lowers the price target from $105 to $71.

Mizuho Maintains Outperform on Zoom Communications, Lowers Price Target to $71

<ul>
<li>ELYXYB&#xAE; is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1</li>
<li>According to market data from 2018, it was found that migraine was more severe than other types of headaches and it impacted more than 2.7 million Canadians, with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.2</li>
<li>There is strong evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for migraine. ELYXYB&#xAE; (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3 &nbsp;</li>
</ul>
PALO ALTO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has received approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB&#xAE;'s acute treatment of migraine with or without aura in Canada.
Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use. ELYXYB&#xAE;'s product profile mapped with a high degree of certainty to these stated unmet needs. In clinical studies, patients treated with ELYXYB&#xAE; demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in approximately 50% of patients.4,5
"We welcome the approval of ELYXYB&#xAE; (celecoxib oral solution) to the acute treatment options for nearly five million Canadians living with migraine. This unique option has proven efficacy and safety that can help patients achieve rapid pain freedom,"&nbsp;said Dr. Christine Lay, Professor of Neurology and Founding Director of the Headache program at the University of Toronto.
"Canada is consistently among the top 10 global pharmaceutical markets. It is the second largest export destination for U.S. pharmaceuticals. It is also a strategic market for expansion globally, providing opportunities for increased international recognition and regulatory harmonization. We are very excited to expand the use of ELYXYB&#xAE; to Canada, which is especially meaningful given the drug is manufactured in Canada, and to start helping Canadian patients who suffer from acute migraine," said Dmitri Lissin, MD, SVP and Chief Medical Officer of Scilex.

SCLX

Scilex Announces Approval Of New Drug Submission From Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy And Neurological Sciences For ELYXYB's Acute Treatment of Migraine With or Without Aura In Canada

On April 15, 2025, Satellogic Inc. (the "Company") entered into a&nbsp;securities purchase agreement&nbsp;(the "Purchase Agreement") with the purchaser party thereto, pursuant to which the Company agreed to issue and sell in a registered direct offering (the "Offering"), 6,451,612 shares (the "Shares") of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at an offering price of $3.10 per share. The gross proceeds to the Company from the Offering are approximately $20.0 million, before deducting the Placement Agent's (as defined below) fees and estimated offering expenses payable by the Company. Closing of the Offering is expected to occur on April 16, 2025, subject to satisfaction of customary closing conditions.

Offerings

SATL

Satellogic Entered Into $20M Securities Purchase Agreement; To Issue And Sell 6,451,612 Shares At $3.10 Per Share

WIIM

Mirion Technologies shares are trading lower after Citigroup cut its price target on the stock from $20 to $17.

At a time when buzzwords and high-frequency trading tend to get all the attention, Argent Capital Management has taken a lower-key — but more strategic — approach. The St. Louis active asset manager has launched <a href="https://www.benzinga.com/etfs">two new ETFs</a>: the Argent Large Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIG#NASDAQ">ABIG</a>) and the Argent Focused Small Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIL#NASDAQ">ALIL</a>). These complement the firm&#8217;s already existing Mid Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMID#NASDAQ">AMID</a>), providing a complete array of U.S. equity exposure that adheres to a rather old-fashioned policy: invest in good companies and let them compound.
Also Read:<a href="https://www.benzinga.com/25/04/44800249/wisdomtrees-fund-just-got-a-makeover-and-its-built-for-market-chaos"> WisdomTree Fund Gets A Makeover That&#8217;s Built For Market Chaos</a>
Argent&#8217;s strategy focuses on the idea it calls &#8220;enduring businesses&#8221; — companies with steadily increasing cash flows, sound capital allocation habits and a lasting competitive advantage. &#8220;We think of it as the economic version of a well-built house that stands strong in all weather. We look closely at how a company reinvests its profits, manages debt, and maintains its edge over competitors. Even as markets rapidly evolve, these fundamental strengths rarely go out of style,&#8221; ABIG portfolio manager Jed Ellerbroek, Jr., told Benzinga.
These are not big, index-hugging funds. Each is constructed with conviction: about 30 to 35 names in ABIG and 35 to 45 in ALIL. That focused method reflects Argent&#8217;s view that meaningful long-term outperformance results from extensive fundamental research and allowing great businesses to do what they do best—compound cash flows over time.
&#8220;Good capital allocation is like planting trees today, knowing they&#8217;ll provide shade in the future. It takes patience,&#8221; Ellerbroek said. &#8220;We seek companies that consistently reinvest cash wisely to fuel long-term growth. When volatility hits, our conviction in these disciplined firms allows us to look beyond short-term and hold positions confidently for years, compounding returns along the way.&#8221;
In today&#8217;s market, that conviction causes them to be overweight in sectors like consumer discretionary and industrials within ABIG. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is the fund&#8217;s largest holding and a key driver of that discretionary tilt. Argent also prefers stocks like Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>), Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) and Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) for their consistent cash flows and resilient business models. At the same time, they&#8217;re underweight in consumer staples, which they consider less attractive compared to some industrials.
Also Read: <a href="https://www.benzinga.com/25/04/44799456/chip-shock-3-hot-semiconductor-etfs-to-watch-as-trumps-tariff-bomb-ticks">Chip Shock: 3 Hot Semiconductor ETFs To Watch As Trump&#8217;s Tariff Bomb Ticks</a>
In ALIL — the small-cap cousin — Argent is making the most of financials and housing-related consumer discretionary names. Ellerbroek cites strong long-term growth opportunities and favorable valuations in both areas. Conversely, the team is cautious about a few companies that don&#8217;t have their quality-first approach. 
&#8220;For ALIL, our small cap strategy, we&#8217;re overweight consumer discretionary, especially housing-related names, given their attractive long-term growth potential,&#8221; he said. &#8220;We're also overweight in financials, thanks to compelling secular trends and reasonable valuations. Meanwhile, we're cautious on healthcare, largely due to our aversion to unprofitable biotech businesses.&#8221;
That research-led approach is particularly important in the small-cap space, where analyst coverage can be thin and market narratives can shift quickly. According to Ellerbroek, the firm conducts small-cap due diligence more like private equity investors than public market traders. &#8220;We're asking ourselves, &#8216;Would we want our own families to own this business?&#8217; This mindset ensures we invest only in businesses we deeply understand and believe can compound value over time.&#8221;
<a href="https://www.prweb.com/releases/argent-capital-management-adds-two-etfs-to-its-growing-lineup-of-investment-solutions-302423047.html">Argent&#8217;s </a>commitment to quality applies to risk management as well. Volatility isn&#8217;t risk; owning lousy businesses is. &#8220;Owning exceptionally high-quality companies, we can confidently look beyond short-term fluctuations, knowing these businesses are built to adapt and thrive over the long term,&#8221; Ellerbroek said.
With three concentrated ETFs now accessible for large-, mid- and small-cap stocks, Argent views a natural opportunity for advisers to create an all-weather core equity portfolio with their funds. ABIG represents a solid large-cap anchor, AMID focuses on mid-cap growth opportunities, and ALIL provides access to emerging opportunities in the small-cap universe.
In a market filled with passive approaches and moment-in-the-sun thematic ETFs, Argent is counting on something that has remained consistent: fundamental research, patience and the compounding power of quality businesses.
As a parting thought, summarizing Argent's investment approach, Ellerbroek told Benzinga, &#8220;We invest in a select group of great businesses that steadily compound cash flow and have lasting competitive advantages &#8211; because in investing, short-term thinking rarely wins; patience usually does.&#8221;
Next Up: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44799117/us-iran-talks-fuel-oil-rally-here-are-5-energy-etfs-in-the-radar">US-Iran Talks Fuel Oil Rally: Here Are 3 Energy ETFs In The Radar</a></li>
</ul>
Photo: Shutterstock

New ETFs

Exclusives

Interview

ABIG

ALIL

AMID

AMZN

CPRT

Exclusive: Argent's New ETFs Are Not Chasing AI Or Meme Stocks, Here's What They're Buying Instead

Barclays analyst Dan Levy maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Equal-Weight and lowers the price target from $10 to $8.

Barclays Maintains Equal-Weight on Ford Motor, Lowers Price Target to $8

Mizuho analyst Siti Panigrahi maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Outperform and lowers the price target from $320 to $275.

Comments

BFF BK SPA by BFF BK SPA

Notizie

Ultime notizie per BFF BK SPA by BFF BK SPA (OTC:BFFBF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO